Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : Tevjf source : Www.biospace.com save search
Teva’s New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiveness and Patient Satisfaction for HD Chorea with the 4-week Titration Kit for AUSTEDO® (deutetrabenazine) Tablets
Published: 2024-04-16 (Crawled : 13:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.23%
H: 0.23%
C: -1.28%
austedo for meeting
Teva Confirms Efficacy and Safety of AJOVY® (fremanezumab) for the Prevention of Migraine With Results from Phase 3 Trial in China
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -1.01%
H: 2.04%
C: 1.17%
ajovy for teva trial migraine china results
Teva to Host Conference Call to Discuss First Quarter 2024 Financial Results at 8 a.m. ET on May 8, 2024
Published: 2024-04-09 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.7%
H: 0.07%
C: -0.92%
first conference teva financial results
Teva and mAbxience Announce Strategic Global Licensing Agreement for Oncology Biosimilar Candidate
Published: 2024-04-04 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
candidate biosimilar global for teva agreement
Teva Presents New Data Supporting Safety, Tolerability and Target Engagement of Anti-TL1A (TEV-‘574) Antibody at the 2024 ECCO Annual Meeting
Published: 2024-02-20 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 2.72%
H: 0.0%
C: -0.8%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 1.31%
H: 0.67%
C: -0.91%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 2.53%
H: 0.0%
C: 0.0%
antibody meeting teva
Teva Canada Named by Forbes as No. 1 Canadian Employer in Drugs & Biotechnology Industry
Published: 2024-02-07 (Crawled : 13:30) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
canada teva
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
Published: 2024-01-18 (Crawled : 00:00) - biospace.com/
EXEL | $22.51 0.09% 0.09% 2.3M
|
Health Technology
|
| O: -0.31%
H: 0.0%
C: -0.89%
cabometyx patent
MedinCell’s partner Teva Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable (LAI)
Published: 2024-01-09 (Crawled : 20:00) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
teva study
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
Published: 2024-01-02 (Crawled : 00:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.29%
H: 3.53%
C: 1.91%
conference year teva financial results
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
Published: 2023-12-06 (Crawled : 10:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.1%
H: 1.09%
C: -2.38%
ajovy obesity migraine
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
Published: 2023-11-17 (Crawled : 16:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 0.91%
H: 2.6%
C: 2.38%
HALO M | $38.64 2.2% 2.15% 1.3M
|
Health Technology
|
| O: 0.94%
H: 1.8%
C: 0.1%
forteo approval teva
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
Published: 2023-11-13 (Crawled : 13:30) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.92%
H: 4.53%
C: 2.56%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.5%
H: 0.0%
C: 0.0%
RPRX | News | $28.17 1.0% 0.99% 1.8M
|
Health Technology
|
| O: -0.44%
H: 0.59%
C: 0.04%
pharma royalty teva program
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
Published: 2023-11-08 (Crawled : 14:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 2.54%
H: 3.23%
C: -1.29%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
revenue teva financial results
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
Published: 2023-10-17 (Crawled : 08:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.69%
H: 1.27%
C: -0.23%
ajovy depression teva migraine study
Teva Leverages Market-leading Temperature and Theft Tracking from FourKites to Deliver Critical Medicines Around the World
Published: 2023-10-12 (Crawled : 13:00) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
| Email alert
Add to watchlist
world teva
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-10-04 (Crawled : 08:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: 1.46%
H: 0.21%
C: -5.65%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
disease treatment collaboration teva sanofi
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
Published: 2023-10-03 (Crawled : 13:00) - biospace.com/
ALVO | News | $13.23 2.64% 2.57% 1.7M
|
n/a
|
| O: 2.22%
H: 0.87%
C: -0.65%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: -1.6%
H: 0.36%
C: -0.46%
KMDA | News | $5.05 -0.98% -0.99% 27K
|
Health Technology
|
| O: 0.1%
H: 0.74%
C: -1.67%
xolair biosimilar commercialization agreement
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
Published: 2023-09-06 (Crawled : 23:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.31%
H: 0.1%
C: -0.52%
MS | News 0 d | $90.66 0.44% 0.07% 8.1M
|
Finance
|
| O: -1.87%
H: 0.0%
C: 0.0%
conference global teva
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
TEVA | $12.86 0.63% 0.0% 10M
|
Health Technology
|
| O: -0.31%
H: 0.1%
C: -0.52%
austedo congress teva
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.